Sinografin Generic Name & Formulations
Diatrizoate meglumine 527mg, iodipamide meglumine 268mg; per mL; soln for intrauterine instillation; contains sodium 0.91mg/mL, organically bound iodine 380mg/mL.
Radiopaque contrast medium.
Single-dose vial (10mL)—10
Sinografin Dosage and Administration
See literature for information on administration and radiography. Empty bladder before exam. 3–4mL administered in fractional doses of approx. 1mL are usually adequate to visualize the uterus; an additional 3–4mL will demonstrate the tubes. Total doses of 1.5–10mL have been used.
Pregnancy. During menstrual period. External genitalia or genital tract infection. Within 30 days of curettage or conization or within 6 months following termination of pregnancy.
Sinografin Boxed Warnings
Should be performed by personnel trained in diagnostic procedures that involve radiopaque diagnostic agents. Carcinoma of the uterus and/or uterine/tubes; possible dispersion of carcinogenic cells during procedure. History of asthma/allergy. Nursing mothers.
May interfere with thyroid tests.
Sinografin Adverse Reactions
Dizziness, syncope, hypotension, chills, fever, nausea, vomiting, abdominal pain and tenderness, hypersensitivity reactions; rare: bradycardia, hypotension, cardiac arrest, death.
Sinografin Clinical Trials
Sinografin Patient Counseling